176 related articles for article (PubMed ID: 38239355)
21. A Pilot Study on the Utility of Serum Metabolomics in Neuroblastoma Patients and Xenograft Models.
Beaudry P; Campbell M; Dang NH; Wen J; Blote K; Weljie AM
Pediatr Blood Cancer; 2016 Feb; 63(2):214-20. PubMed ID: 26481088
[TBL] [Abstract][Full Text] [Related]
22. Detection of PI3K inhibition in human neuroblastoma using multiplex luminex bead immunoassay: a targeted approach for pathway analysis.
Lang WH; Sandoval JA
J Biomol Screen; 2014 Oct; 19(9):1235-45. PubMed ID: 25092063
[TBL] [Abstract][Full Text] [Related]
23. The dual HDAC and PI3K inhibitor, CUDC‑907, inhibits tumor growth and stem‑like properties by suppressing PTX3 in neuroblastoma.
Li M; Hu Y; Wang J; Xu Y; Hong Y; Zhang L; Luo Q; Zhen Z; Lu S; Huang J; Zhu J; Zhang Y; Que Y; Sun F
Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38063204
[TBL] [Abstract][Full Text] [Related]
24. B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met/AKT/mTOR/IRF-1 axis in neuroblastoma.
Sha YL; Liu Y; Yang JX; Wang YY; Gong BC; Jin Y; Qu TY; Xia FT; Han L; Zhao Q
J Exp Clin Cancer Res; 2022 Oct; 41(1):314. PubMed ID: 36284313
[TBL] [Abstract][Full Text] [Related]
25. Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma.
Nozato M; Kaneko S; Nakagawara A; Komuro H
Int J Oncol; 2013 Jan; 42(1):134-40. PubMed ID: 23135478
[TBL] [Abstract][Full Text] [Related]
26. Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma.
Wang Y; Chen K; Cai Y; Cai Y; Yuan X; Wang L; Wu Z; Wu Y
J Exp Clin Cancer Res; 2017 Aug; 36(1):111. PubMed ID: 28814318
[TBL] [Abstract][Full Text] [Related]
27. Repurposing a plant alkaloid homoharringtonine targets insulinoma associated-1 in N-Myc-activated neuroblastoma.
Chen C; Wu J; Hicks C; Lan MS
Cell Signal; 2023 Sep; 109():110753. PubMed ID: 37301315
[TBL] [Abstract][Full Text] [Related]
28. Development and validation of a nomogram based on common biochemical indicators for survival prediction of children with high-risk neuroblastoma: A valuable tool for resource-limited hospitals.
Wu R; Li X; Chen Z; Shao Q; Zhang X; Tang W; Hu B
BMC Pediatr; 2023 Aug; 23(1):426. PubMed ID: 37633889
[TBL] [Abstract][Full Text] [Related]
29. [A comprehensive analysis of potential prognostic biomarkers for MYCN-amplified neuroblastoma].
Fan X; Lu HT; Hou L; Zhang L; Yang BY; Chen WM; Zhang HY; Chen X; Li FJ
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Mar; 22(3):262-268. PubMed ID: 32204764
[TBL] [Abstract][Full Text] [Related]
30. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
31. PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
Geng X; Xie L; Xing H
Technol Cancer Res Treat; 2016 Oct; 15(5):716-22. PubMed ID: 26224681
[TBL] [Abstract][Full Text] [Related]
32. TRAIL induces pro-apoptotic crosstalk between the TRAIL-receptor signaling pathway and TrkAIII in SH-SY5Y cells, unveiling a potential therapeutic "Achilles heel" for the TrkAIII oncoprotein in neuroblastoma.
Gneo L; Ruggeri P; Cappabianca L; Farina AR; Di Ianni N; Mackay AR
Oncotarget; 2016 Dec; 7(49):80820-80841. PubMed ID: 27821809
[TBL] [Abstract][Full Text] [Related]
33. Exosomal hsa-piR1089 promotes proliferation and migration in neuroblastoma via targeting KEAP1.
Wang H; Shi B; Zhang X; Shen P; He Q; Yin M; Pan Y; Ma J
Pathol Res Pract; 2023 Jan; 241():154240. PubMed ID: 36436316
[TBL] [Abstract][Full Text] [Related]
34. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
35. Gene-expression-based analysis of local and metastatic neuroblastoma variants reveals a set of genes associated with tumor progression in neuroblastoma patients.
Nevo I; Oberthuer A; Botzer E; Sagi-Assif O; Maman S; Pasmanik-Chor M; Kariv N; Fischer M; Yron I; Witz IP
Int J Cancer; 2010 Apr; 126(7):1570-81. PubMed ID: 19739072
[TBL] [Abstract][Full Text] [Related]
36. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.
Kushner BH; Cheung NV; Modak S; Becher OJ; Basu EM; Roberts SS; Kramer K; Dunkel IJ
Int J Cancer; 2017 Jan; 140(2):480-484. PubMed ID: 27649927
[TBL] [Abstract][Full Text] [Related]
37. Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis.
Xia J; Zhang H; Hu Q; Liu SY; Zhang LQ; Zhang A; Zhang XL; Wang YQ; Liu AG
J Huazhong Univ Sci Technolog Med Sci; 2017 Oct; 37(5):649-660. PubMed ID: 29058276
[TBL] [Abstract][Full Text] [Related]
38. Use of Attribute Driven Incremental Discretization and Logic Learning Machine to build a prognostic classifier for neuroblastoma patients.
Cangelosi D; Muselli M; Parodi S; Blengio F; Becherini P; Versteeg R; Conte M; Varesio L
BMC Bioinformatics; 2014; 15 Suppl 5(Suppl 5):S4. PubMed ID: 25078098
[TBL] [Abstract][Full Text] [Related]
39. A novel clinical tool and risk stratification system for predicting the event-free survival of neuroblastoma patients: A TARGET-based study.
Li M; Duan X; Li C; You D; Liu L
Medicine (Baltimore); 2023 Sep; 102(38):e34925. PubMed ID: 37746942
[TBL] [Abstract][Full Text] [Related]
40. Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma.
Su Y; Wang L; Wang X; Yue Z; Xing T; Zhao W; Zhao Q; Duan C; Huang C; Han Y; Qiu L; Cheng X; Liu Y; Ma X
Cancer Med; 2019 Apr; 8(4):1558-1566. PubMed ID: 30793512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
